Generation HD-2

Generation HD-2 This study will evaluate the safety, biomarkers, and efficacy of tominersen compared with a placebo in participants with prodromal and early manifest Huntington’s Disease. Inclusion Criteria: Visit link below for more info: Ages Eligible for Study:   25 Years to 50 Years   (Adult) Sexes Eligible for Study:   All Generation HD-2 Link […]

Generation HD-2 Read More »